South America Pharmaceutical Plastic Packaging Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

South America Pharmaceutical Plastic Packaging Market Trends and Insights

Expansion of Generic-Drug Manufacturing

Brazil's generic drug sector is the largest single source of packaging demand in the region. ANVISA indicated that a large share of generic drugs sold in Brazil were produced domestically in recent years. The continued localization of production supports recurring demand for bottles, blister packs, and closures. Argentina's Ministry of Health reported that generic medications accounted for a substantial share of its pharmaceutical market. Larger domestic manufacturers are narrowing their polymer grade panels, which reduces the requalification burden under ANVISA requirements. This standardization favors packaging suppliers with approved material specifications and high-throughput PP lines. Generic production also concentrates purchasing decisions among major drug manufacturers. That concentration can make volume contracts more predictable for converters that already meet the required standards. PP bottles, blister packs, and polypropylene closures remain aligned with the needs of high-volume tablet and solid-dose production. Suppliers must also maintain reliable quality documentation because established grades are difficult to replace once a drug product is qualified. The South America pharmaceutical plastic packaging market benefits from this base of routine demand even when specialized formats receive more attention. Local manufacturing capacity, therefore, supports volume continuity across several national procurement systems.

Growth in Biologics and Injectable Therapies

Biologics are shifting demand toward primary containers with stricter performance requirements. COP and COC received formal European Pharmacopeia recognition in 2025 through new chapters from the European Directorate for the Quality of Medicines.^{[1]European Directorate for the Quality of Medicines, “European Pharmacopoeia Online,” Council of Europe, edqm.eu} The recognition helps reduce documentation barriers for biosimilar developers using these materials. COP and COC provide low extractables, low protein adsorption, optical clarity, and dimensional precision. These attributes are important for biologics and injectable fill-finish operations. The South America pharmaceutical plastic packaging market consequently has a higher need for qualified cartridges and related primary components. West Pharmaceutical Services raised its organic revenue outlook, while High-Value Product component revenue increased significantly, indicating sustained global investment in injectable containment systems. Locally produced GLP-1 pen devices have also created demand for cartridge packaging at Brazilian fill-finish sites. Existing regional supply has limited capacity for COP and COC cartridges manufactured to the required tolerances, creating import dependency while qualification programs develop. Suppliers that combine material expertise with validated manufacturing can address this requirement.

Serialization and Traceability Upgrades

Serialization is changing the technical requirements for pharmaceutical packaging in Brazil and Argentina. Brazil's 2026 DataMatrix requirement for secondary drug packaging adds pressure to improve printability and in-line inspection. Argentina's Disposición 2891/2026 required QR or Data Matrix codes on secondary pharmaceutical packaging from May 16, 2026.^{[2]Administración Nacional de Medicamentos, Alimentos y Tecnología Médica, “Disposición ANMAT 2891/2026, Códigos 2D Para Medicamentos,” Murten, murten.com.ar} The rule provided a six-month transition period for GS1-compliant coding. These measures require converters to evaluate substrates, inks, primers, and vision systems. The South America pharmaceutical plastic packaging market gains demand for technically compliant films and containers as these rules take effect. Glossy PP and PET surfaces can require surface treatment or primers to keep codes durable through distribution. This requirement is particularly relevant where packaging is handled across long supply chains and variable climates. Suppliers with validated printing processes are better placed to meet the new requirements. Smaller converters that rely on untreated commodity films may face qualification barriers. Similar frameworks under consideration in Colombia and Chile extend the relevance of these investments beyond Brazil and Argentina. Traceability upgrades, therefore, make technical capability a more important basis for supplier selection.

Shift Toward Lightweight and Recyclable Packaging

Packaging buyers are increasing their focus on recyclable formats and lower material use. Constantia Flexibles' PERPETUA ALTA is a mono-polypropylene laminate for pharmaceutical sachets and stick packs. The laminate received Class B certification from RecyClass and was a finalist in the 2026 De Gouden Noot packaging innovation award. Its design is compatible with established PP recycling streams. The development shows that recyclable pharmaceutical formats are moving into commercial applications. It also provides a reference for converters evaluating mono-material flexible packs. Klöckner Pentaplast completed its restructuring in January 2026, eliminating EUR 1.3 billion in funded debt and receiving EUR 349 million in new capital. The company can direct capital toward kpNext recyclable pharmaceutical blister films that fit PP, PET, and HDPE recycling streams. Pharmaceutical-grade recycled PP and PET remain unavailable at scale in South America. Recyclable designs, therefore, still depend mainly on virgin resin until collection and reverse-logistics systems improve.

Availability of Alternative Packaging Materials

Glass remains an established alternative for injectable pharmaceutical products. Borosilicate Type I vials, ampoules, and prefillable glass syringes have established regulatory acceptance. SCHOTT Pharma reported continued revenue growth, reflecting sustained demand for glass pharmaceutical packaging.^{[3]SCHOTT Pharma AG and Co. KGaA, “SCHOTT Pharma With Strong Third Quarter and on Track for Planned Growth,” SCHOTT Pharma Investor Relations, schott-pharma.com} Glass-to-polymer conversion requires requalification studies, stability data, and regulatory submissions. These requirements delay material changes for many mid-tier drug manufacturers. Aluminum foil laminates and non-plastic blister materials also compete in selected solid-dose applications. The cost and duration of qualification can limit polymer conversion in tender-led public programs. Price pressure makes it harder to justify a switch when established glass formats already meet the drug product specification. High-value biologics can support polymer adoption where break resistance, weight, or device integration are important. However, glass remains relevant in vials, ampoules, and syringe applications. The South America pharmaceutical plastic packaging market must therefore compete on a clear technical or operating benefit. Material choice will continue to depend on product stability, regulation, and the cost of changing validated packaging systems.

Volatility in Polymer and Additive Costs

PP and PET pricing is linked to global propylene and paraxylene derivative markets. These inputs can be affected by crude oil movements, logistics disruptions, and refinery capacity changes. South American converters also import a significant share of pharmaceutical-grade resin. Currency depreciation, especially in Argentina, can raise local input costs even when global commodity prices are stable. Public tenders often fix per-unit drug procurement prices for extended periods. This limits a converter's ability to pass input increases through the supply chain.

Specialty additives add a second cost risk for pharmaceutical-grade materials. UV stabilizers, antioxidants, and nucleating agents come from a concentrated international supplier base. Smaller regional buyers can face allocation constraints during periods of tight supply. Margin pressure may reduce the capital available for new equipment and material qualification. It can also make price negotiations with drug manufacturers more difficult. The South America pharmaceutical plastic packaging market remains exposed, where packaging suppliers cannot align resin contracts with customer pricing terms.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Raw Material: Polypropylene Holds Volume Leadership While COP/COC Advances in Biologics

Polypropylene held 29.23% of the South America pharmaceutical plastic packaging market share in 2025. Its position reflects compatibility with solid oral dosage forms and an economical fit for high-volume generic production. PP bottles, closures, and strip packs support Brazil's domestic generic drug manufacturing base. Regulatory acceptance from ANVISA and ANMAT also supports continued use of these established materials. PET provides chemical resistance and optical clarity for liquid oral formulations and selected parenteral containers. HDPE is used for moisture-sensitive products because its barrier performance exceeds standard PP grades in those applications. LDPE remains relevant for eye drops, nasal sprays, squeeze containers, and unit-dose formats. Its lower oxygen barrier limits its use compared with HDPE and PP in more demanding applications.

COP and COC are projected to expand at an 8.11% CAGR through 2031, the highest rate among material categories. Their low extractables profile and glass-like clarity support biologics and biosimilar fill-finish requirements. Their dimensional precision also fits cartridges and other injection-related components. EDQM's 2025 pharmacopoeial chapters make submissions easier for developers using COP and COC. Bio-based and recycled plastics are still at an early adoption stage because qualified pharmaceutical-grade recyclate is not available in sufficient regional volumes. Supply arrangements with qualified overseas resin producers can give converters a compliance advantage as sustainability requirements tighten. Material selection in the South America pharmaceutical plastic packaging industry is consequently separating between broad-volume generic needs and more demanding injectable applications.

By Product Type: Bottles Anchor Demand While Pre-Fillable Syringes and Cartridges Lead Growth

Bottles and solid containers accounted for 29.44% of the South America pharmaceutical plastic packaging market size in 2025. This share reflects the large volume of oral tablets, capsules, and related generic medicines made in Brazil and Argentina. High-throughput bottling lines are designed around public procurement volumes and established dispensing practices. Blister packs and strip packs also have a substantial role in over-the-counter and hospital-dispensed solid doses. PVC-PVDC and aluminum-plastic constructions remain common in these formats. Closures, caps, and lids maintain demand because every primary container requires an engineered closing component. Vials and ampoules serve parenteral medicines in both glass and plastic constructions. IV bags and flexible bags remain important for institutional infusion therapy and single-use contamination control.

Pre-fillable syringes and cartridges are projected to expand at an 8.23% CAGR through 2031. Demand comes from self-administration for diabetes, obesity, autoimmune conditions, and oncology. SCHOTT Pharma introduced a ready-to-use COC polymer cartridge for biologics, biosimilars, and emergency drugs in 2025. The product reflects the wider move toward ready-to-use delivery systems at fill-finish operations. Pouches, stick packs, and sachets address pediatric, geriatric, and home-care needs where unit dosing is important. ANVISA Good Manufacturing Practice requirements and ISO 15223-related labeling needs also shape product qualification. The South America pharmaceutical plastic packaging market has room for suppliers that can support both established oral formats and higher-specification injectable products.

By Packaging Format: Rigid Packaging Leads While Flexible Formats Serve New Uses

Rigid packaging held 72.13% of the South America pharmaceutical plastic packaging market share in 2025. Bottles, blister cavities, vials, and pre-fillable syringes are central to hospital pharmacy and retail dispensing practices. These formats provide tamper evidence and clear unit-dose presentation. The installed base of generic manufacturing lines also represents long-term capital investment in rigid container systems. These lines cannot be easily shifted to flexible alternatives. ANVISA Good Manufacturing Practice guidance requires reliable container-closure integrity testing. Rigid systems often provide a more established route through multiyear stability studies. The result is a durable role for rigid formats across the region's broad pharmaceutical product base.

Flexible packaging is projected to expand at an 8.42% CAGR through 2031, the highest rate across the reported segmentation types. Home-care dispensing, ambulatory treatment, and single-dose sachets support this momentum. Flexible packs can serve pediatric and geriatric patients who need convenient doses. Mono-PP laminates and recyclable blister films are lowering the qualification barrier for more sustainable flexible options. Multilayer barrier films can also support cold-chain biologics in home-care distribution. Lower weight and thermal-response characteristics are relevant for last-mile delivery across varied geographies. Flexible formats complement rigid packaging rather than displace it across the South America pharmaceutical plastic packaging market.

By Route of Drug Delivery: Oral Products Lead While Parenteral Delivery Accelerates

The oral route accounted for 46.23% of packaging demand in 2025. Tablets, capsules, syrups, and oral powders dominate many public health procurement programs. Brazil's domestic production of generic drugs supports demand for PP bottles, PET containers, blister packs, and closures. ANVISA reported that domestically produced drugs accounted for most generic drugs sold in Brazil. Ophthalmic and nasal formats remain smaller specialty applications associated with eye drops, nasal sprays, and related unit-dose containers. Topical and transdermal products also support localized pain management and hormone therapy protocols, maintaining a diverse demand base beyond oral medicines.

Parenteral and injectable delivery is projected to expand at an 8.22% CAGR through 2031. Biosimilar launches, hospital formularies, and self-administration programs are supporting this direction. Pen injectors and autoinjectors require cartridges, needle shields, and luer-lock closures at each fill-finish stage. The growth of teleconsultations in Brazil supports the infrastructure case for home-based care. Injectable formats require strong barrier performance and reliable dimensional tolerances. These technical requirements encourage packaging suppliers to develop specialized polymer capabilities. The South America pharmaceutical plastic packaging market is increasingly linked to the operating requirements of injectable drug delivery systems.

By End-User: Pharma Manufacturers Lead Procurement While Home Care Gains Ground

Pharma manufacturers held 64.36% of end-user demand in 2025. This concentration reflects industrial-scale purchasing of packaging materials and components. Large generic manufacturers set material specifications, contract volumes, and pricing terms for their suppliers. The role is especially visible in Brazil and Argentina, where domestic firms supply public tender programs. Standardization around ANVISA-approved grades can improve production consistency for these manufacturers. It can also make established converter relationships more durable. CDMOs form a secondary user group where fill-finish capacity is being developed. Hospitals and clinics continue to procure IV bags, pre-filled syringes, and other institutional formats.

Home-care settings are projected to expand at an 8.16% CAGR through 2031. Diabetes, oncology, and autoimmune care are moving toward more self-administered treatment in Brazil, Colombia, and Chile. EMS launched Olire and Lirux injectable pens through Brazilian pharmacy chains in August 2025. The launch covered obesity and diabetes applications and created a domestic channel for self-injection devices. Hospital and clinic procurement will remain a steady contributor because infusion therapy and hospital pharmacies still require disposable formats. The home-care channel adds to these needs instead of replacing them. The South America pharmaceutical plastic packaging market needs packaging that supports patient handling, safe delivery, and reliable medicine protection outside clinical settings.

Geography Analysis

Brazil accounted for 35.66% of the South America pharmaceutical plastic packaging market share in 2025. Its domestic generic drug production provides the region's largest concentration of routine packaging demand. ANVISA's 2026 DataMatrix requirement requires Brazilian converters to improve printability and in-line inspection capabilities. The October 2025 introduction of GTIN validation in electronic invoices adds to the traceability requirement. Brazil's Regulatory Agenda for 2026-2027 covers 161 priority topics, increasing the importance of packaging documentation and stability testing. These compliance demands require coordination among drug makers, material suppliers, and converters.

Brazil's manufacturing investments also support future primary packaging volumes. Laboratório Cristália assumed operations of Takeda's former Jaguariúna solid-medicines plant in August 2026. The facility had an existing ANVISA Good Manufacturing Practices certification, which substantially increased Cristália's capacity, depending on the formulation type. Brazil's manufacturing base has high volumes of solid oral dosage production. This structure reinforces demand for PP bottles, blister packs, closures, and related formats. Suppliers with traceability and quality systems can benefit from these capacity additions. Brazil will remain the principal geographic focus for the South America pharmaceutical plastic packaging market. Brazilian demand includes the daily packaging needs of locally produced generic medicines. This makes delivery reliability important for suppliers serving high-volume production lines. Solid-dose output requires consistent bottles, closures, and blister-pack materials. Packaging validation must remain aligned with each medicine's approved specification. The certification status of a production site also affects the timing of new packaging orders. Existing Good Manufacturing Practices documentation can shorten the path to resumed production. Manufacturing transfers require coordination between drug makers and packaging suppliers. That coordination extends to material specifications, closures, labels, and secondary-packaging codes. The focus on local output reduces dependence on packaged imports for routine medicines. It also makes Brazilian production decisions significant for regional packaging suppliers. Technical converters can differentiate through traceability, printing, and quality-control systems. These capabilities are relevant for both routine generic medicines and more specialized formats. Brazil's demand base combines established volume with rising compliance requirements. This combination supports investment in production systems that can handle different rigid and flexible formats.

Colombia is projected to expand at an 8.18% CAGR through 2031, the fastest reported country rate. Its risk-based inspection approach supports pharmaceutical facility approvals and makes Bogotá a location for fill-finish activity. Argentina is responding to ANMAT's traceability requirements through faster qualification of print-compatible PP and PET films. Chile is advancing sustainability requirements that encourage recyclable PET and mono-PP substrates among importers and repackagers. Peru, Ecuador, Bolivia, Uruguay, and Paraguay remain smaller markets with distinct distribution roles. Peru and Colombia benefit from documentation coordination under Andean Community health policy. Uruguay and Paraguay function largely as import channels for Brazilian and Argentine packaged medicines under Mercosur preferences. This geographic diversity requires suppliers to adapt packaging documentation and logistics to national operating conditions.